Addex regains rights to GABAB positive allosteric modulator portfolio from Indivior

ADXN•2026-09-25

Addex Therapeutics regained rights to its GABAB positive allosteric modulator portfolio from Indivior, gaining full ownership of the returned development candidate and freedom to pursue new indications.

1. Rights returned

Addex Therapeutics said it regained rights to its GABAB positive allosteric modulator portfolio from Indivior. The company said it now has full ownership of the returned development candidate and freedom to pursue new indications.

Addex regains rights to GABAB positive allosteric modulator portfolio from Indivior

1. Rights returned

Related News

ROI-AI challenges fuel trading's old guard: Russell

Oppenheimer cuts Acadia Pharmaceuticals’ target price to $23 from $25

North Sea gas maintenance schedule adds Barrow outage

Hawaiian Electric prepares for power outages as storm approaches

Gen Digital Inc.: RBC cuts target price to $26 from $30